Prolexys Pharmaceuticals

Biotechnology ResearchUnited States2-10 Employees

Prolexys Pharmaceuticals, Inc. is a United States-based biotechnology company focused on discovering small molecule drugs that engage novel therapeutic targets, with a primary emphasis on cancer and cardiovascular diseases. The company leverages proprietary proteomics-based techniques to rapidly identify compounds that interact with chosen targets. This targeted discovery work yields a pipeline of product candidates expected to address areas of unmet medical need. Founded in 2001, the company is headquartered in Salt Lake City, Utah.

Its pipeline includes a solid tumor oncology program with a small molecule clinical candidate showing selective anti-tumor activity, a colon cancer program targeting the beta-catenin signaling cascade, and antagonists of HSP20 identified as protein interaction inhibitors in asthma and vasorelaxation contexts. The company positions itself in the biopharmaceutical discovery space by combining target identification, validation, and early-stage development capabilities to support partners pursuing novel cancer and cardiovascular therapies.

Sign up for free to view info

Email Format Employee directory